Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 1, 2021
July 3, 2021
cd630104-b6ee-4993-a2ff-85effca3e866
Related Documents
Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Guidance for Industry, IRBs, and Clinical Investigators
Guidance DocumentJuly 27, 2026Office of the Commissioner
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry
Guidance DocumentDecember 19, 2018Center for Drug Evaluation and Research
Premenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry
Guidance DocumentJune 17, 2021Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.